Kyverna Therapeutics, Inc. Share Price & Technical Analysis
KYTX · $8.67 (-2.58%)
Healthcare / Biotechnology
$8.67
-2.58%
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product can…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 3 years shown)
-1% return in May, -4% avg return in past 3 year May month.
-2% return in 2026, -28% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -16% | 4% | 9% | 2% | -1% | – | – | – | – | – | – | – | -2% |
| 25 | -16% | -12% | -34% | 21% | 9% | 19% | 20% | 6% | 58% | 17% | 8% | 24% | 119% |
| 24 | – | -10% | -10% | -39% | -17% | -50% | 18% | -9% | -38% | -2% | 21% | -38% | -174% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$596.22M
P/E ratio
—
52W high
$13.67
52W low
$2.43
Volume
4,99,406
Beta
2.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Kyverna Therapeutics, Inc. share price today?
- Kyverna Therapeutics, Inc. (KYTX) last traded around $8.67 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KYTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KYTX. Download the app for real-time alerts.
- How can I analyze Kyverna Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.